press releases

Preliminary full year 2021 net revenues of $535 million and fourth quarter net revenues of $133 million DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated in early Q2 2022 given limited total number of events to date in fast-recruiting trial Novocure to present at… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. EST on… Read More

The property will provide space for Novocure’s growing workforce, and house a world-class training and development center ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) to help deepen the understanding… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 33rd Annual 2021 Piper Sandler Healthcare Conference on November 30, 2021. Mr. Doyle and Ms. Cordova will… Read More

Final data from LUNAR trial anticipated year-end 2022 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune checkpoint inhibitors or docetaxel for treatment of… Read More

Median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up Partial or complete response was detected in 24% of patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the… Read More

An oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society… Read More

Quarterly net revenues of $133.6 million with 77% gross margin Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across… Read More